The development of apalutamide for the treatment of prostate cancer.
Pedro Isaacsson VelhoPedro Tofani Sant' AnnaRommel Fabricio Pereira da SilvaRafael Dal Ponte FerreiraFernando Castilho VeneroPublished in: Expert opinion on drug discovery (2020)
Apalutamide has become a relevant therapy for patients with nmCRPC and mHSPC for its benefit in delaying metastasis in addition to its improvement of overall survival, without compromising the quality of life. Apalutamide should be considered as a standard-of-care for patients with nmCRPC and patients with mHSPC.